[Effect of local application of allicinvia gastroscopy on cell proliferation and apoptosis of progressive gastric carcinoma].
OBJECTIVE
To study the effects of local application of allicin via gastroscopy on progressive gastric carcinoma, and to investigate its possible mechanisms.


METHODS
Eighty patients with progressive gastric adenocarcinoma, whose diagnosis was confirmed by gastroscopy and pathological examination, were assigned to 2 groups, 40 in each group. Forty-eight hours before operation, allicin was infused via gastroscopy to the lesion region of patients in the allicin group, and normal saline was infused instead to those in the control group. The gastric carcinoma tissue gotten from gastrectomy was taken to determine the percentage of cells in various cell cycle phases ( G0/ G1, S and G2/M), the cell apoptosis rate, proliferation index value and apoptosis related gene protein such as Fas, Bax and Bcl-2 by flow cytometry.


RESULTS
In the allicin group, the cell apoptosis rate was 9.60 +/- 1.52%, the percentage of cell in G0/G1 phase was 72.12 +/- 8.35%, in G2/M phase 9.54 +/- 3.20%, and PI 27.80 +/- 8.35, while in the control group, the corresponding data was 2.20 +/- 0.58%, 69.56 +/- 5.15%, 13.20 +/- 3.05%, and 30.40 +/- 5.15, respectively, and significant difference in all the 4 indexes could be found between the two groups (P < 0.05, P < 0.01). Moreover, allicin showed effects in up-regulating the protein expressions of apoptosis promoting gene Bax and apoptosis initiating gene Fas (P < 0.05, P < 0.01), and down-regulating that of anti-apoptosis gene Bcl-2 (P < 0.05).


CONCLUSIONS
Local application of allicin via gastroscopy can inhibit the cell growth and proliferation of progressive gastric carcinoma, and can also promote gastric carcinoma cell apoptosis.
Zhang
Zhi-dong
ZD
Department of General Surgery, Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang.
Li
Yong
Y
Jiao
Zhi-kai
ZK
D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects*; D002453:Cell Cycle / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects*; D004220:Disulfides; D005260:Female; D005434:Flow Cytometry; D005773:Gastroscopy; D006801:Humans; D008297:Male; D008875:Middle Aged; D008517:Phytotherapy; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D013441:Sulfinic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D051028:bcl-2-Associated X Protein / Q000096:biosynthesis; D019014:fas Receptor / Q000096:biosynthesis
D000890:Anti-Infective Agents; D004220:Disulfides; C491901:FAS protein, human; D013441:Sulfinic Acids; D051028:bcl-2-Associated X Protein; D019014:fas Receptor; C006452:allicin